Eye Risks of Ozempic: What You Need to Know About Semaglutide and NAION

Eye Risks of Ozempic: What You Need to Know About Semaglutide and NAION

At Ticho Eye Associates (TEA), we stay vigilant in tracking emerging treatments and their potential effects on eye health. One such medication that has garnered significant attention is semaglutide, commonly known by its brand names Ozempic and Wegovy, used to manage type 2 diabetes and obesity. While it's an effective treatment for these conditions, recent studies have raised concerns about its potential link to nonarteritic anterior ischemic optic neuropathy (NAION)—a condition that can lead to sudden vision loss.

The Growing Concern: Semaglutide and NAION

A recent study published in JAMA Ophthalmology found that patients taking semaglutide may have an increased risk of developing NAION. Patients with diabetes on semaglutide had a 4 times higher risk, and those with obesity had a 7 times higher risk. This potential association has led to questions about the safety of semaglutide, particularly for individuals with other risk factors for optic nerve damage.

The Mechanism: Hypotension and Fluid Loss

One of the key concerns raised by experts is the gastrointestinal side effects associated with semaglutide, such as nausea, vomiting, and diarrhea. These side effects can cause dehydration and low blood pressure, conditions that could decrease blood flow to the optic nerve and increase the risk of NAION. The timing of the NAION diagnosis—often occurring shortly after starting semaglutide—supports the theory that hypoperfusion (reduced blood flow) to the optic nerve could trigger the condition.

What Does This Mean for TEA Patients?

If you're taking semaglutide or considering it as part of your treatment plan for diabetes or obesity, it's important to be aware of potential eye health risks. While more research is needed to confirm the link between semaglutide and NAION, regular eye exams are crucial for early detection of any changes in vision.

At Ticho Eye Associates, we are committed to ensuring comprehensive care. If you're on semaglutide, we recommend routine screenings to monitor for diabetic retinopathy, NAION, and other ocular complications that could arise, especially for those with diabetes or obesity.

Stay Informed and Stay Safe

We are closely monitoring studies on semaglutide and its effects on eye health. If you're concerned about potential risks, reach out to us at any of our locations to schedule an eye exam. Early detection and proactive care can help ensure your vision remains protected.

Chicago Ridge

10436 Southwest Highway,

Chicago Ridge, IL 60415

Phone: (708) 873-0088 

Munster 

10436 N. Centennial Dr. Ste H

Munster, IN 46321

Phone: (708) 873-0088

Tinley Park

18210 S. LaGrange Rd. Ste 210 

Tinley Park, IL 60487

Phone: (708) 873-0088

To read more about the semaglutide study and its potential link to NAION, check out the original article in JAMA Ophthalmology here: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255#google_vignette. 

Stay informed and take the necessary steps to protect your vision!